OTCMKTS:ZYXIZynex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.97 -0.68 (-6.38 %) (As of 04/5/2020 11:37 AM ET) Add Compare Share Today's Range$9.76Now: $9.97▼$10.8050-Day Range$9.16MA: $11.38▼$14.4052-Week Range$4.60Now: $9.97▼$15.27Volume235,999 shsAverage Volume345,565 shsMarket Capitalization$327.14 millionP/E Ratio45.32Dividend YieldN/ABeta1.05 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Zynex has a potential upside of 55.5% from its current price of $9.97.Amount of Analyst CoverageZynex has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesZynex has received 179 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZynex has received 143 “underperform” votes. (Add your “underperform” vote.)Community SentimentZynex has received 55.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote “Outperform” if you believe ZYXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Zynex is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 17.86% in the coming year, from $0.28 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 45.32, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 10.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 45.32, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 12.15.Price to Book Value per Share RatioZynex has a P/B Ratio of 66.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ZYXI Previous Symbol CUSIPN/A CIK846475 Webhttp://www.zynexmed.com/ Phone303-703-4906Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.23Price-To-Earnings Trailing P/E Ratio45.32 Forward P/E Ratio35.61 P/E GrowthN/A Sales & Book Value Annual Sales$23.43 million Price / Sales13.96 Cash Flow$0.56 per share Price / Cash Flow17.91 Book Value$0.15 per share Price / Book66.47Profitability EPS (Most Recent Fiscal Year)$0.22 Net Income$7.36 million Net Margins33.33% Return on Equity152.81% Return on Assets95.46%Miscellaneous EmployeesN/A Outstanding Shares32,812,000Market Cap$327.14 million Next Earnings DateN/A OptionableNot Optionable Receive ZYXI News and Ratings via Email Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter. OTC:ZYXI Rates by TradingView Zynex (OTCMKTS:ZYXI) Frequently Asked Questions How has Zynex's stock been impacted by COVID-19 (Coronavirus)? Zynex's stock was trading at $11.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZYXI stock has decreased by 10.1% and is now trading at $9.97. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Zynex? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zynex. How were Zynex's earnings last quarter? Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings data on Thursday, February, 27th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.01. The business earned $14.16 million during the quarter, compared to analyst estimates of $14.25 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's earnings history. What guidance has Zynex issued on next quarter's earnings? Zynex issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $63.5 million. What price target have analysts set for ZYXI? 3 equities research analysts have issued 12-month price objectives for Zynex's stock. Their forecasts range from $13.00 to $18.50. On average, they anticipate Zynex's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 55.5% from the stock's current price. View analysts' price targets for Zynex. Has Zynex been receiving favorable news coverage? News coverage about ZYXI stock has been trending very negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zynex earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutZynex. Who are some of Zynex's key competitors? Some companies that are related to Zynex include Natus Medical (NTUS), InMode (INMD), Viewray (VRAY), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Stereotaxis (STXS), BioLife Solutions (BLFS), Cutera (CUTR), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP) and Fc Global Realty (FCRE). What other stocks do shareholders of Zynex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Primo Water (PRMW), Aytu Bioscience (AYTU), FuelCell Energy (FCEL), Melinta Therapeutics (MLNT), Altria Group (MO), Penumbra (PEN), Aldeyra Therapeutics (ALDX), BioDelivery Sciences International (BDSI), Codexis (CDXS) and Catalyst Pharmaceuticals (CPRX). Who are Zynex's key executives? Zynex's management team includes the following people: Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)Mr. David B. Mogill, VP of OperationsMr. Robert Bird, VP of MarketingMr. Steve Siefring, Director of Bus. Devel. What is Zynex's stock symbol? Zynex trades on the OTCMKTS under the ticker symbol "ZYXI." How do I buy shares of Zynex? Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zynex's stock price today? One share of ZYXI stock can currently be purchased for approximately $9.97. How big of a company is Zynex? Zynex has a market capitalization of $327.14 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View additional information about Zynex. What is Zynex's official website? The official website for Zynex is http://www.zynexmed.com/. How can I contact Zynex? Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Why is the Consumer Price Index (CPI) important?
